Close

Ratings by Maxim Group (Naz Rahman)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
10/11/2022 scPharmaceuticals SCPH Maintain Buy
(N/A)
 
 
  Details
10/4/2022 Clene, Inc. CLNN Maintain Buy
(N/A)
 
 
  Details
8/22/2022 Clarus CRXT Downgrade Hold
(Buy)
0.21
(0.10)
-52.38% Details
8/19/2022 Palisade Bio Inc. PALI Downgrade Hold
(Buy)
0.16
(4.08)
2450% Details
8/2/2022 scPharmaceuticals SCPH New Coverage Buy
(N/A)
4.89
(6.93)
41.72% Details
7/1/2022 9 Meter Biopharma NMTR Downgrade Hold
(Buy)
0.26
(1.73)
565.38% Details
6/21/2022 9 Meter Biopharma NMTR Maintain Buy
(N/A)
 
 
  Details
6/9/2022 Virpax Pharmaceuticals, Inc. VRPX New Coverage Buy
(N/A)
1.55
(0.83)
-46.45% Details
5/9/2022 180 Life Sciences Corp. ATNF Downgrade Hold
(Buy)
1.31
(0.36)
-72.52% Details
4/19/2022 Processa Pharmaceuticals PCSA New Coverage Buy
(N/A)
2.87
(1.86)
-35.19% Details
2/25/2022 NEXGEL NXGL New Coverage Buy
(N/A)
1.81
(1.21)
-33.15% Details
1/7/2022 Quoin Pharmaceuticals QNRX New Coverage Buy
(N/A)
1.74
(1.69)
-2.87% Details
1/7/2022 NeuroSense Therapeutics Ltd. NRSN New Coverage Buy
(N/A)
2.53
(1.63)
-35.57% Details
12/7/2021 First Wave BioPharma, Inc. FWBI Downgrade Hold
(Buy)
1.40
(0.79)
-43.57% Details
10/1/2021 First Wave BioPharma, Inc. FWBI Maintain Buy
(N/A)
 
 
  Details
9/29/2021 Clarus CRXT New Coverage Buy
(N/A)
5.61
(0.10)
-98.22% Details
9/15/2021 180 Life Sciences Corp. ATNF New Coverage Buy
(N/A)
5.67
(0.36)
-93.65% Details
8/31/2021 Palisade Bio Inc. PALI New Coverage Buy
(N/A)
2.73
(4.08)
49.45% Details